Finding markers for niraparib response in advanced ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks for proteins in your blood that might show if niraparib maintenance therapy works well after first platinum chemo. It helps doctors personalize treatment for advanced ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV), specifically high-grade serous or endometrioid type
- You have finished at least 4 cycles of platinum-based chemo and it worked (complete or partial response) or you have no sign of disease
- You are starting niraparib as maintenance therapy per your doctor's prescription
- You are not pregnant, breastfeeding, or planning pregnancy during and 6 months after treatment
- You have not had a PARP inhibitor before (like olaparib, rucaparib, or niraparib itself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called niraparib (Zejula) for women with advanced or relapsed ovarian cancer. It may help keep the cancer from coming back after it has responded to platinum-based chemotherapy. The study focuses on safety and is for women who meet certain health and treatment criteria.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.